BUZZ-PTC Therapeutics falls after withdrawing muscle disorder drug marketing application
Reuters
Feb 13
BUZZ-PTC <a href="https://laohu8.com/S/LENZ">Therapeutics</a> falls after withdrawing muscle disorder drug marketing application
** Shares of PTC Therapeutics PTCT.O fall 5.2% to $67.05 after markets
** Co says it has withdrawn its marketing application resubmission for its muscle disorder drug Translarna
** "FDA shared that based on its review to date, the data in the NDA submission are unlikely to meet the agency's threshold of substantial evidence of effectiveness to support approval of Translarna", says PTCT
** Last year co said the drug will no longer be available for sale in the EU as the European Commission has decided not to renew its marketing authorization
** The drug is designed to boost production of a protein called dystrophin, the absence of which causes muscle weakening in patients with Duchenne muscular dystrophy
** PTCT was up 68.3% in 2025
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.